Condition
Afib
Total Trials
7
Recruiting
1
Active
2
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 7 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
Early P 1 (1)
P 1 (1)
Trial Status
Completed4
Recruiting1
Withdrawn1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (7)
Showing 7 of 7 trials
NCT07087587Not ApplicableRecruitingPrimary
Sleep Apnea Triggers of Atrial Fibrillation: N-of-1 Randomized Control Trial (SPARTA):
NCT03929718Early Phase 1Active Not RecruitingPrimary
Efficacy of Aldosterone Antagonist Therapy for Prevention of New Atrial Fibrillation
NCT06335498Completed
Further Study of AFGen1 Clinical Performance
NCT06076798Completed
Clinical Performance of AFGen1
NCT05295056Completed
Clinical Performance of the AFGen1 Device Over a 7-day Period
NCT01952925Not ApplicableWithdrawnPrimary
Combined Afib Ablation and RA Denervation for the Maintenance of Sinus Rhythm and Management of Resistant Hypertension
NCT01997905Phase 1Completed
Stroke Feasibility Study
Showing all 7 trials